NCT06474091

Liquid Biopsy MonitORing Of CholangioCarcinOma for Treatment Response and Prognostic Outcomes (MOROCCO)

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study explores the potential value of a new blood test approach to detect measurable residual disease or early recurrence/progression in patients with cholangiocarcinoma.

Detailed description

PRIMARY OBJECTIVES: I. To estimate the association of PUMA levels from peripheral blood with disease progression (radiographically or clinically) in patients that are candidates for curative surgical intervention of cholangiocarcinoma. Ia. Pre- and post-neoadjuvant-treatment PUMA levels will be associated with treatment response to neoadjuvant therapy (short term progression). Ib. Pre-surgical and post-surgical PUMA levels will be associated with progression free survival. II. To estimate the association of PUMA levels from peripheral blood with postoperative survival in patients treated for cholangiocarcinoma. OUTLINE: This is an observational study. Patients undergo collection of blood samples and have their medical records reviewed on study. Patients also undergo collection of archived tissue samples on study.

Conditions

• Cholangiocarcinoma

Interventions

Type	Name	Description
OTHER	Non-Interventional Study	Non-Interventional Study

Timeline

• Start date: 2024-05-08
• Primary completion: 2029-05-08
• Completion: 2029-05-08
• First posted: 2024-06-25
• Last updated: 2026-03-16

Locations

1 site across 1 country: United States